Clin2
NCT06532799Possibly a fitRecruiting

TIL therapy with pembrolizumab for advanced stomach and esophageal cancer

Stomach CancerStomach Cancer RecurrentStomach Cancer, AdenocarcinomaEsophageal CancerEsophageal Cancer Metastatic to BoneEsophageal Cancer Metastatic to LungEsophageal Cancer Metastatic to Liver

Treatments studied

Part of Cancer, Digestive system clinical trials.

This trial tests a combination of immune cells from your tumor (TILs) and an immunotherapy drug (pembrolizumab) for stomach or esophageal cancer that has spread or returned after other treatments. It may help if standard options have failed.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
75 people
Ages
16 years to 90 years
Study type
Interventional

Who can take part

  • You are between 16 and 90 years old.
  • You have stomach or esophageal cancer that has spread or come back, and you've tried standard treatments or none are available.
  • You must have a tumor that can be biopsied or removed to get immune cells, or fluid from the body where those cells can be found.
  • You have at least one tumor that can be measured on scans.
  • Your blood counts, kidney, and liver function are within certain healthy limits.
  • You cannot be pregnant or breastfeeding, and must use effective birth control during and for 1 year after treatment.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06640582Recruiting· Phase 1/Phase 2
TIL therapy with pembrolizumab for advanced brain cancer

This trial tests a new treatment for advanced brain cancers like glioma and meningioma. It combines your own immune cells (tumor-infiltrating lymphocytes or TILs) with an immunotherapy drug (pembrolizumab) to help your body fight the tumor. It's for people who have tried other treatments without success or have no standard options left.

Beijing, Beijing Municipality
NCT06532812Recruiting· Phase 1/Phase 2
TIL therapy plus immunotherapy for advanced breast cancer

This trial tests a personalized therapy using your own immune cells (TILs) combined with immunotherapy to fight advanced breast cancer that has not responded to other treatments. It may help if you have a tumor that can be biopsied and you are generally healthy enough for the procedures.

Beijing, Beijing Municipality
NCT06538012Recruiting· Phase 1/Phase 2
Tumor immune cells plus pembrolizumab for advanced lung cancer

This trial tests a new approach: taking immune cells from your own tumor (TILs), growing them in the lab, then giving them back to you along with the immunotherapy drug pembrolizumab. It is for people with advanced lung cancer who have run out of standard options.

Beijing, Beijing Municipality
NCT06530303Recruiting· Phase 1/Phase 2
Personalized immune cell therapy for colorectal cancer

This trial tests a treatment made from your own immune cells (called TILs) that are taken from your tumor, grown in a lab, and given back to you along with immunotherapy. It is for people with advanced colon or rectum cancer who have run out of standard options.

Beijing, Beijing Municipality
NCT05087745Recruiting· Early Phase 1
TIL therapy for advanced solid tumors

This trial tests a treatment that uses your own immune cells, called TILs, to fight advanced solid tumors. The cells are taken from a biopsy of your tumor, multiplied in a lab, and then given back to you. It might help if you have tried other treatments without success, or if no standard treatment is available.

Hangzhou, Zhejiang
NCT07255664Recruiting· Phase 1/Phase 2
TIL therapy for advanced colorectal or prostate cancer

This trial tests a new type of immunotherapy that uses your own white blood cells (TILs) to fight advanced colorectal or prostate cancer. You will have surgery to remove a tumor, then your TIL cells are grown in a lab and given back to you along with other treatments to boost your immune system.

Frankfurt

Hear when a new Esophageal Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.